Linked Life Data

15611513

Source:http://linkedlifedata.com/resource/pubmed/id/15611513

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
24
pubmed:dateCreated
2004-12-21
pubmed:abstractText
Germline inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene causes the von Hippel-Lindau hereditary cancer syndrome, and somatic mutations of this gene have been linked to the development of sporadic hemangioblastomas and clear-cell renal carcinomas. The VHL tumor suppressor protein (pVHL), through its oxygen-dependent polyubiquitylation of hypoxia-inducible factor (HIF), plays a central role in the mammalian oxygen-sensing pathway. This interaction between pVHL and HIF is governed by post-translational prolyl hydroxylation of HIF in the presence of oxygen by a conserved family of Egl-nine (EGLN) enzymes. In the absence of pVHL, HIF becomes stabilized and is free to induce the expression of its target genes, many of which are important in regulating angiogenesis, cell growth, or cell survival. Moreover, preliminary data indicate that HIF plays a critical role in pVHL-defective tumor formation, raising the possibility that drugs directed against HIF or its downstream targets (such as vascular endothelial growth factor) might one day play a role in the treatment of hemangioblastoma and renal cell carcinoma. On the other hand, clear genotype-phenotype correlations are emerging in VHL disease and can be rationalized if pVHL has functions separate from its control of HIF.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0732-183X
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
22
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
4991-5004
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:15611513-Adrenal Gland Neoplasms, pubmed-meshheading:15611513-Carcinoma, Renal Cell, pubmed-meshheading:15611513-Diagnosis, Differential, pubmed-meshheading:15611513-Genes, Tumor Suppressor, pubmed-meshheading:15611513-Genetic Predisposition to Disease, pubmed-meshheading:15611513-Genotype, pubmed-meshheading:15611513-Germ-Line Mutation, pubmed-meshheading:15611513-Humans, pubmed-meshheading:15611513-Kidney Neoplasms, pubmed-meshheading:15611513-Phenotype, pubmed-meshheading:15611513-Pheochromocytoma, pubmed-meshheading:15611513-Protein Processing, Post-Translational, pubmed-meshheading:15611513-Tumor Suppressor Proteins, pubmed-meshheading:15611513-Ubiquitin-Protein Ligases, pubmed-meshheading:15611513-Von Hippel-Lindau Tumor Suppressor Protein, pubmed-meshheading:15611513-von Hippel-Lindau Disease
pubmed:year
2004
pubmed:articleTitle
Role of VHL gene mutation in human cancer.
pubmed:affiliation
Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
pubmed:publicationType
Journal Article, Review